

Approved by:



CERTIFICATE

2023

Molekularpathologie-BW GbR
Schloßstraße 56
70176 Stuttgart
Germany

has successfully completed the proficiency test

BRCA1/2 Mutation Analysis (MolPath)

(Trial Period 06.11.2023 - 17.11.2023)

Berlin, March 15, 2024

Prof. Dr. med. Dr. h.c. Manfred Dietel
Quality in Pathology - QuIP GmbH

Thomas Pilz, Managing Director
Quality in Pathology - QuIP GmbH

Lead panel institute of the proficiency test:
Prof. Dr. med. Arndt Hartmann, University Hospital Erlangen, Germany

This certificate includes the separate individual evaluation of the test and the corresponding proficiency test report.

This proficiency test was organized by:
Qualitätssicherungs-Initiative Pathologie QuIP GmbH /
Reinhardtstr. 1 / 10117 Berlin / office@quip.eu / www.qualityinpathology.com

